Joint Scientific Assessment
Biogen announces phase 2 data for cutaneous lupus erythematosus
The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity
Invited, but not equipped: patient involvement needs more than an open door
Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.
The outcomes are already chosen. So when can patients really shape them?
Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.
Long-term clinical trial engagement is a behavioural challenge – not just an informational one
Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.
Patients are telling the truth — just not to you
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
When what matters to patients is hard to measure
Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.
Novartis announces trial results for remibrutinib in relapsing multiple sclerosis
MS affects nearly three million people worldwide and has three main types
Pfizer announces phase 3 results for nonsegmental vitiligo treatment
Litfulo delivered significant, clinically meaningful improvements for both face and body
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Veradermics’ oral treatment for female pattern hair loss delivers positive study results
Pattern hair loss affects around 30 million women and 50 million men in the US
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.